COGT Cogent Biosciences, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1622229 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-38.5%
TTM EPS YoY-10.2%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-99.6%
ROA-64.8%
ROIC (approx.)-89.9%
Asset turnover—
Leverage & solvency
Liabilities / assets38.0%
Debt / equity0.43x
Current ratio10.99x
Interest coverage-85.23x
Cash quality & payout
Operating cash flow / net income0.79x
Accruals ratio-13.3%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $75.10M | $70.81M | $75.36M | $75.56M | $68.99M | $62.20M | $63.03M | $62.05M |
| SG&A expense | $42.09M | $31.83M | $28.24M | $23.93M | $14.37M | $13.38M | $11.90M | $11.69M |
| Operating income | -$117.18M | -$102.64M | -$103.61M | -$99.49M | -$83.36M | -$75.58M | -$74.93M | -$73.73M |
| Interest expense | $1.24M | $1.22M | $1.21M | $1.29M | $1.46M | $314,000 | — | — |
| Net income | -$111.43M | -$96.41M | -$97.35M | -$102.49M | -$80.93M | -$73.53M | -$71.99M | -$67.93M |
| EBITDA | -$116.61M | -$101.90M | -$102.98M | -$98.83M | -$82.71M | -$74.93M | -$74.29M | -$73.06M |
| EPS (basic) | -0.59 | -0.52 | -0.53 | — | -0.50 | -0.53 | -0.52 | — |
| EPS (diluted) | -0.59 | -0.52 | -0.53 | — | -0.50 | -0.53 | -0.52 | — |
| Weighted avg. shares (diluted) | 173.13M | 171.01M | 162.19M | — | 137.55M | 114.47M | 113.31M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $217.46M | $181.17M | $241.21M | $312.01M | $125.63M | $127.60M | $126.00M | $98.17M |
| Short-term investments | $573.67M | $611.13M | $625.17M | $588.75M | $265.59M | $110.25M | $119.66M | $188.91M |
| Current assets | $803.58M | $804.82M | $877.80M | $910.36M | $397.24M | $245.01M | $252.88M | $296.47M |
| PP&E, net | $4.31M | $4.78M | $5.30M | $5.46M | $5.27M | $5.85M | $6.45M | $6.47M |
| Total assets | $832.14M | $834.55M | $903.01M | $937.61M | $425.93M | $274.82M | $283.80M | $327.90M |
| Current liabilities | $73.12M | $59.30M | $57.98M | $63.95M | $62.25M | $58.42M | $49.32M | $55.71M |
| Long-term debt | $223.74M | $223.46M | $223.17M | $222.90M | $44.25M | $43.95M | — | $0 |
| Total debt | $223.74M | $223.46M | $223.17M | $222.90M | $44.25M | $43.95M | — | $0 |
| Total liabilities | $315.88M | $302.16M | $295.31M | $301.24M | $123.47M | $119.78M | $64.80M | $71.61M |
| Shareholders' equity | $516.26M | $532.39M | $607.69M | $636.37M | $302.46M | $155.04M | $219.00M | $256.29M |
| Net debt | $6.28M | $42.28M | -$18.04M | -$89.12M | -$81.38M | -$83.65M | — | -$98.17M |
| Shares outstanding | 173.98M | 171.60M | 170.77M | 160.98M | 139.83M | 113.93M | 113.86M | 110.46M |
| Cash flow statement | ||||||||
| Operating cash flow | -$80.79M | -$77.27M | -$86.88M | -$79.11M | -$64.29M | -$54.54M | -$66.51M | -$60.58M |
| Capital expenditure | $108,000 | $370,000 | $449,000 | $811,000 | $65,000 | $131,000 | $547,000 | $75,000 |
| Free cash flow | -$80.89M | -$77.64M | -$87.33M | -$79.92M | -$64.35M | -$54.67M | -$67.06M | -$60.65M |
| Investing cash flow | $37.31M | $14.28M | -$36.46M | -$322.77M | -$155.05M | $8.91M | $69.38M | $61.67M |
| Financing cash flow | $79.76M | $2.96M | $52.54M | $588.67M | $217.37M | $47.23M | $24.97M | $26,000 |
| Depreciation & amortization | $572,000 | $741,000 | $626,000 | $664,000 | $641,000 | $655,000 | $640,000 | $675,000 |
| Stock-based compensation | $16.87M | $17.11M | $16.91M | $15.75M | $10.60M | $9.72M | $10.01M | $9.98M |
Free plan shows the latest 8 periods; Pro shows all 39 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.